Who Owns Medpace Company?

Medpace Bundle

Get Full Bundle:

	PESTLE	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Medpace?

Understanding a company's ownership is key to grasping its strategic path and accountability. Medpace Holdings, Inc., a global clinical contract research organization, offers comprehensive clinical development services for biotech, pharma, and medical device sectors.

Founded in 1992, Medpace has grown into a major player, employing around 6,000 associates globally as of June 30, 2025. The company focuses on speeding up therapeutic development, particularly for small to mid-size biopharma firms.

Medpace's financial standing is robust, with trailing 12-month revenue reaching $2.16 billion as of March 31, 2025, and a market capitalization of $8.96 billion as of July 18, 2025. This analysis will explore its ownership evolution, from its founding to its current public status, including board influence and recent trends.

The company's operational framework and market positioning are significantly influenced by its ownership structure, which has evolved since its inception. Examining this structure provides insight into the company's governance and future direction, including its approach to services like those detailed in the Medpace PESTEL Analysis.

Medpace was established in July 1992 by Dr. August Troendle, who continues to lead the company as its Chief Executive Officer and Chairman of the Board. Dr. Troendle's extensive background in both the regulatory and pharmaceutical industries, including his time at the FDA and Sandoz, shaped his vision for a comprehensive contract research organization (CRO).

Founding Vision Dr. August Troendle founded Medpace with a vision to create a full-service CRO. His goal was to integrate medical expertise with operational and regulatory professionals. Early Contributors Key industry physicians like Dr. Jonathan Issacsohn and Dr. Evan Stein were vital in early study completion. Dr. David Orloff also played a significant role in metabolic disease research. Private Equity Acquisition In 2014, Medpace was acquired by Cinven, a global private equity firm, for $915 million. This marked a significant shift in the company's ownership structure. Post-Acquisition Ownership Following the acquisition, Cinven and Medpace Investors, LLC (MPI) held approximately 75% and 25% of Medpace Holdings, Inc., respectively. MPI represents certain Medpace employees. Dr. Troendle's Role Dr. August Troendle remains the sole founder and holds a substantial ownership stake. His leadership continues to guide the company's strategic direction. Early Ownership Details Precise equity splits for the company's private phase are not publicly disclosed. The focus was on building a strong foundation for growth and clinical research.

The initial ownership structure during Medpace's private phase, while not detailed publicly regarding specific percentages, involved its founder, Dr. August Troendle, and key early contributors who were instrumental in advancing the company's clinical research capabilities. A significant transformation in Medpace's ownership occurred in 2014 when Cinven acquired the company for $915 million. This transaction led to a new ownership configuration where Cinven and Medpace Investors, LLC (MPI), an entity representing certain employees, became the primary stakeholders. Immediately after this acquisition, Cinven held approximately 75% of Medpace Holdings, Inc., with MPI holding around 25%. This period marked a transition towards institutional ownership, influencing the company's trajectory and strategic decisions, which can be further understood by examining the Marketing Strategy of Medpace.

Key Ownership Milestones

Medpace's ownership journey includes its founding by Dr. August Troendle and a significant acquisition by private equity. These events have shaped the company's current shareholder landscape.

• Founded in July 1992 by Dr. August Troendle.
• Dr. Troendle also serves as CEO and Chairman of the Board.
• Acquired by Cinven in 2014 for $915 million.
• Post-acquisition, Cinven and MPI held initial stakes of approximately 75% and 25% respectively.

Medpace SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Medpace Holdings, Inc. underwent a significant transformation by becoming a publicly traded entity on August 11, 2016, through an initial public offering. This transition followed its acquisition by a private equity firm in 2014, marking a shift from private equity control to public market ownership.

The ownership structure of Medpace Holdings, Inc. is diverse, reflecting its status as a publicly traded company. As of July 14, 2025, the company has approximately 28.7 million shares outstanding, with ownership distributed among institutional investors, company insiders, and the general public.

Medpace Ownership Breakdown

Institutional investors hold a dominant stake in Medpace, indicating significant confidence from large financial entities.

• As of March 31, 2025, 1101 institutional owners held 29,938,048 shares, representing approximately 77.98% of the company's stock.
• Key institutional shareholders include BlackRock, Inc., Vanguard Group Inc., Invesco Ltd., Wasatch Advisors Inc., and State Street Corp.
• Dr. August Troendle, the founder and CEO, is a major individual shareholder, holding between 19% and 21% of the company's stock.
• As of May 29, 2024, Dr. Troendle directly owned 654,656 shares, with additional indirect holdings.
• This insider ownership by the founder is crucial for aligning leadership interests with shareholder value, as detailed in the Brief History of Medpace.

Medpace PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The governance of Medpace Holdings, Inc. is significantly influenced by its Board of Directors, with Dr. August J. Troendle holding key leadership positions. As the founder, CEO, and Chairman of the Board since 1992, Dr. Troendle plays a pivotal role in the company's strategic direction and operational oversight, impacting Medpace ownership and its overall trajectory.

Medpace operates under a straightforward one-share-one-vote system for its common stock, meaning each share held translates to one vote on company matters. As of March 21, 2024, the company had 30,983,185 shares of common stock outstanding and eligible to vote. The company's proxy statement, filed on April 3, 2024, detailed the voting procedures for the May 17, 2024, Annual Meeting of Stockholders. Looking ahead to the 2025 Annual Meeting of Shareholders on May 16, 2025, the election of ten directors is scheduled, with all directors being elected annually by a majority of the votes cast. While there are no indications of dual-class shares, Dr. Troendle's substantial ownership, combined with his executive and board leadership, grants him considerable influence over Medpace company owners and decisions. Historically, a voting agreement existed that linked Dr. Troendle's votes to Cinven's share percentage, but this arrangement concluded with Cinven's divestment. To foster alignment with shareholders, the Board has implemented share ownership guidelines for its executive officers and non-employee directors, including a requirement for the CEO to accumulate and retain a specified number of shares over a five-year period. There have been no recent public reports of significant proxy contests or activist campaigns that have altered Medpace's fundamental governance structure. Understanding the Competitors Landscape of Medpace can provide further context on market dynamics affecting ownership.

Medpace Shareholder Voting Power

Medpace utilizes a standard one-share-one-vote structure, ensuring all common stockholders have equal voting rights. Dr. August J. Troendle, as founder and CEO, holds significant voting power due to his substantial share ownership.

• 30,983,185 common shares outstanding as of March 21, 2024.
• All directors are elected annually by a majority of votes cast.
• Dr. Troendle's dual role as CEO and Chairman centralizes influence.
• Share ownership guidelines aim to align executive and director interests with those of other Medpace shareholders.

Medpace Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

In recent years, Medpace has focused on enhancing shareholder value through active capital management, including substantial share repurchases. The company's commitment to returning capital to shareholders is evident in its significant buyback programs, demonstrating confidence in its financial health and future growth prospects.

Medpace has demonstrated robust financial performance, with Q2 2025 revenue reaching $603.3 million, a 14.2% increase year-over-year. The company projects full-year 2025 revenue between $2.420 billion and $2.520 billion, indicating a growth of 14.7% to 19.5%. This growth, combined with share repurchases, has positively influenced earnings per share, which saw a 12.7% rise in Q2 2025.

Institutional Investor Confidence

Institutional investors held approximately 77.98% of Medpace shares as of March 31, 2025. Significant inflows from these large investment funds over the past year highlight growing confidence in the company's performance and outlook.

Founder's Stake and Activity

Founder Dr. August Troendle remains a significant insider, though he has engaged in some share sales, such as disposing of 9,682 shares in May 2024 for over $3.8 million. He continues to hold substantial direct and indirect ownership interests.

Shareholder Value Enhancement

The company's aggressive share repurchase programs, including the recent $1.0 billion increase to its buyback authorization, underscore a strategic focus on enhancing shareholder value. These actions reflect management's belief in the company's intrinsic worth and its ability to generate strong returns.

Ownership Structure Stability

There have been no public announcements regarding potential privatization or significant founder exits that would fundamentally alter Medpace's current ownership structure. The company's ownership remains predominantly institutional, with key insiders maintaining significant stakes.

Medpace Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔